Literature DB >> 12369863

Small molecule peptidomimetic ligands of neurotrophin receptors, identifying binding sites, activation sites and regulatory sites.

H Uri Saragovi1, Maria Clara Zaccaro.   

Abstract

Neurotrophins (NTFs) are a family of polypeptide growth factors that control the apoptotic death or survival, growth, and differentiation of neurons. NTFs also regulate several other cell populations such as lymphoid, epithelial, oligoglia, and mast cells. Disregulation of the NTFs or their receptors plays a key role (etiological or upstream) in certain human pathologies. Hyperactivity may lead to inflammatory pain, or some forms of cancer by autocrine/paracrine growth. Loss of activity may lead to neurodegeneration, neuropathic pain, or some forms of cancer by absence of differentiation. Consequently the NTFs and their receptors are important therapeutic targets, and pharmacological modulation may have applications ranging from treatment of chronic or acute neurodegeneration, some forms of cancer, and chronic pain (with agonists); and some forms of cancer or acute pain (with antagonists).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12369863     DOI: 10.2174/1381612023393215

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  8 in total

1.  Role of the conformational versatility of the neurotrophin N-terminal regions in their recognition by Trk receptors.

Authors:  Francesca Stanzione; Luciana Esposito; Antonella Paladino; Carlo Pedone; Giancarlo Morelli; Luigi Vitagliano
Journal:  Biophys J       Date:  2010-10-06       Impact factor: 4.033

2.  A peptidomimetic of NT-3 acts as a TrkC antagonist.

Authors:  Fouad Brahimi; Andrey Malakhov; Hong Boon Lee; Mookda Pattarawarapan; Lubijca Ivanisevic; Kevin Burgess; H Uri Saragovi
Journal:  Peptides       Date:  2009-07-30       Impact factor: 3.750

3.  Bivalent peptidomimetic ligands of TrkC are biased agonists and selectively induce neuritogenesis or potentiate neurotrophin-3 trophic signals.

Authors:  Dianjun Chen; Fouad Brahimi; Yu Angell; Yu-Chin Li; Jennifer Moscowicz; H Uri Saragovi; Kevin Burgess
Journal:  ACS Chem Biol       Date:  2009-09-18       Impact factor: 5.100

Review 4.  Small-molecule modulation of neurotrophin receptors: a strategy for the treatment of neurological disease.

Authors:  Frank M Longo; Stephen M Massa
Journal:  Nat Rev Drug Discov       Date:  2013-07       Impact factor: 84.694

5.  Combinatorial assembly of small molecules into bivalent antagonists of TrkC or TrkA receptors.

Authors:  Fouad Brahimi; Eunhwa Ko; Andrey Malakhov; Kevin Burgess; H Uri Saragovi
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

6.  Pharmacological interrogation of TrkA-mediated mechanisms in hippocampal-dependent memory consolidation.

Authors:  Sylvia Josephy-Hernandez; Iulia Pirvulescu; Mario Maira; Tahar Aboulkassim; Tak Pan Wong; R Anne McKinney; H Uri Saragovi
Journal:  PLoS One       Date:  2019-06-24       Impact factor: 3.240

7.  The Paradoxical Signals of Two TrkC Receptor Isoforms Supports a Rationale for Novel Therapeutic Strategies in ALS.

Authors:  Fouad Brahimi; Mario Maira; Pablo F Barcelona; Alba Galan; Tahar Aboulkassim; Katrina Teske; Mary-Louise Rogers; Lisa Bertram; Jing Wang; Masoud Yousefi; Robert Rush; Marc Fabian; Neil Cashman; H Uri Saragovi
Journal:  PLoS One       Date:  2016-10-03       Impact factor: 3.240

8.  In retinitis pigmentosa TrkC.T1-dependent vectorial Erk activity upregulates glial TNF-α, causing selective neuronal death.

Authors:  Alba Galán; Sean Jmaeff; Pablo F Barcelona; Fouad Brahimi; Marinko V Sarunic; H Uri Saragovi
Journal:  Cell Death Dis       Date:  2017-12-14       Impact factor: 8.469

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.